- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01819519
Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus (CDC/CMV)
Development and Evaluation of a Clinic-Based Screening and Brief Intervention for Changing Behaviors Related to Cytomegalovirus Transmission in Pregnant Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized single-masked clinical trial of behavioral intervention versus standard care of pregnant women lacking evidence of acute CMV infection that have consented to be screened as part of the Maternal Fetal Medicine Units Network multi-centered randomized clinical trial, in which pregnant women are screened with CMV serology for IgM, IgG, and IgG avidity.
Eligible pregnant women will be randomized to one of two treatment groups:
- Control Group - no intervention
- Intervention Group - brief intervention and educational materials Written informed consent will be obtained from patients before they can be screened for the study by CMV testing (IgM, IgG, and IgG avidity) as per the protocol for screening in the MFMU study.
All women presenting for prenatal care no later than 20 weeks gestational age without a known multifetal gestation are eligible for CMV screening Those with evidence of primary infection will be offered participation in the MFMU randomized trial of CMV hyperimmune globulin to prevent congenital infection. Women lacking evidence of acute infection will be eligible for randomization into this study. Patients must be randomized no later than 20 weeks gestation.
If eligible and no more than 20 weeks gestation, the patient will be randomized. If the patient is randomized in the control group, she will continue her routine prenatal care inclusive of the CDC brochure that she received at the time of her venipuncture for serologic screening and assessment of hygiene behaviors. If the patient is randomized into the intervention group, we will deliver a face-face educational intervention during her next routine prenatal visit. In addition to the intervention, the patient will include educational material to take home.
Both groups will be assessed for performance of hygiene behaviors as a baseline assessment at the time of consent. A second assessment will occur at least 12 weeks after enrollment during the third trimester between 28-36 weeks of gestation. The follow-up assessment will be completed by a different research assistant from the unblinded educator. A Kessler 10 (K10) survey will also be completed in addition to the baseline and follow-up assessment.
The follow-up assessment will take place during the participant's third trimester between 28-36 weeks of gestation, depending on duration of enrollment and likelihood of early delivery. The enrollment duration will vary from approximately 14-20 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Women and Infants Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women lacking evidence of acute CMV infection is defined as one of the following: A negative IgM antibody (<1.00 Index) and negative IgG antibody (<6.0 AU/ml) or A negative IgM antibody (<1.00 Index) and positive IgG antibody (≥6.0 AU/ml)
- Gestational age during CMV screening will be no later than 20 weeks based on clinical information and evaluation of the earliest ultrasound.
- Enrollment will occur no later than 20 weeks' gestation.
- Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 20 weeks' by project gestational age is acceptable.
- English and Spanish-speaking women of any age will be offered enrollment
Exclusion Criteria:
- Planned termination of pregnancy
- Women with a previous child with congenital CMV
- Intention of leaving the prenatal practice
- Known major fetal anomalies or demise
- Multiple gestation
- Known HIV infection
- Primary CMV infection, as determined by a positive IgM antibody, a positive IgG antibody and low IgG avidity or positive IgM antibody and negative IgG antibody
- An old and a recent CMV infection, as determined by a positive IgM antibody, positive IgG antibody and high IgG avidity.
- Non-Spanish or English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Standard Prenatal Care
Participants will receive standard prenatal care from the time they are screened for CMV to delivery.
This includes a CMV brochure.
|
|
EXPERIMENTAL: Educational Intervention
This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
|
The patient will told if previously infected or seronegative and what is the risk of the becoming infected.
The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hygiene Behaviors
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
The primary outcome is defined as a change in the participant's hygiene behaviors determined by the differences between the baseline and follow-up behavioral assessment compliance scores.
Each question in these assessments will be assigned a score from 0-5 (5 = desired preventative behavior).
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavior Change based on Serostatus
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Did knowing the serostatus affect hygiene behavior change, as defined by a change in compliance scores between baseline and follow-up visits?
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Change in K10 after Intervention
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Was there a change in stress and anxiety (measured by the K10 assessment scores) before and after the intervention?
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Behavior Change based on Socioeconomics
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Was behavior change influenced by socioeconomic status?
Behavior change is defined by the difference in compliance scores between baseline and follow-up visits
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Racial associations with hygiene behavior change
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Was behavior change influenced by race?
Behavior change is defined by the difference in compliance scores between baseline and follow-up visits
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Behavior Change related to Children at home
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Was behavior change influenced by the number of children living at home?
Behavior change is defined by the difference in compliance scores between baseline and follow-up visits
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Behavior Change and Occupation Association
Time Frame: Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Was behavior change influenced by participants' occupation?
Behavior change is defined by the difference in compliance scores between baseline and follow-up visits
|
Participants will be followed from enrollment (baseline) to 14-20 weeks after enrollment (follow-up)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Brenna Anderson, MD, Women & Infants Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFA-DD-12-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
Clinical Trials on Educational Intervention
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBacterial Infection | Clostridium DifficileUnited States
-
McGill University Health Centre/Research Institute...University of Manitoba; Sunnybrook Health Sciences Centre; University of Alberta and other collaboratorsCompletedPeptic Ulcer Hemorrhage
-
Universidad de GranadaNot yet recruitingAsthma | Allergy
-
Roswell Park Cancer InstituteCompletedCervical Cancer | Breast CancerUnited States
-
US Department of Veterans AffairsDuke UniversityCompletedAccidental FallsUnited States
-
Gary MorrowNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Azienda Unità Sanitaria Locale Reggio EmiliaCompletedMelanoma (Skin) | Educational ProblemsItaly
-
Goethe UniversityUnknownHealth Knowledge, Attitudes, PracticeGermany
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | LymphedemaUnited States
-
Claudia AristizábalUniversidad Nacional de Colombia; Universidad de Santander; Fundación Universitaria...Enrolling by invitationBurnout, Psychological | CaregiversColombia